Aaron Cowen’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Aaron Cowen’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33,333	Closed	-$6K	–	108
2022 Q1	$6K	Hold	33,333	–	–	﹤0.01%	87
2021 Q4	$19K	Hold	33,333	–	–	﹤0.01%	94
2021 Q3	$24K	Hold	33,333	–	–	﹤0.01%	105
2021 Q2	$35K	Hold	33,333	–	–	﹤0.01%	121
2021 Q1	$42K	Buy	+33,333	New	+$54K	﹤0.01%	105

Other funds holding EUCRW

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Aaron Cowen's EUCRW Position: Q2 2022 in Review

Aaron Cowen sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2022, closing a stake of 33,333 shares — an estimated $6K sold.

Aaron Cowen first reported a position in EUCRW in Q1 2021 and held it in 5 quarters. The position peaked at $42K in Q1 2021. 26 funds tracked by Wall St. Rank hold EUCRW as of Q2 2022.

Aaron Cowen reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2022 after selling out during the quarter.
Aaron Cowen sold 33,333 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2022, an estimated $6K.
Aaron Cowen first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 5 quarters.
Aaron Cowen's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $42K in Q1 2021.
26 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2022.

Based on Suvretta Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.